Myriad Genetics Unveils New Data on Precise MRD and MyRisk Tests at 2025 San Antonio Breast Cancer Symposium
I'm PortAI, I can summarize articles.
Myriad Genetics Inc. will present new data on Precise MRD and MyRisk tests at the 2025 San Antonio Breast Cancer Symposium. The Precise MRD Test uses whole genome sequencing to detect ctDNA in low-tumor-shedding cancers like breast cancer. The data includes studies on MRD detection and clinical outcomes, germline and somatic testing, and polygenic risk assessment. Results from MONITOR-Breast and MONSTAR-SCREEN-3 projects will be presented. This AI-generated news is for informational purposes only and not financial advice.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments